至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

On-target restoration of a split T cell-engaging antibody for precision immunotherapy

Nat Commun.. 2019; 
Banaszek A1, Bumm TGP1, Nowotny B1, Geis M1, Jacob K1, Wölfl M2, Trebing J3, Kucka K3, Kouhestani D1, Gogishvili T1, Krenz B1, Lutz J1, Rasche L1, Hönemann D1, Neuweiler H4, Heiby JC4, Bargou RC1,5, Wajant H3, Einsele H1, Riethmüller G6, Stuhler G7.
Products/Services Used Details Operation
Process Development Services Experiments were conducted by GenScript on a Biacore T200. Briefly, a Series S Sensor Chip CM5 was coated with VLαCD3-scFvαHLA-A2 using amine coupling methods. Get A Quote

摘要

T cell-engaging immunotherapies are changing the landscape of current cancer care. However, suitable target antigens are scarce, restricting these strategies to very few tumor types. Here, we report on a T cell-engaging antibody derivative that comes in two complementary halves and addresses antigen combinations instead of single molecules. Each half, now coined hemibody, contains an antigen-specific single-chain variable fragment (scFv) fused to either the variable light (VL) or variable heavy (VH) chain domain of an anti-CD3 antibody. When the two hemibodies simultaneously bind their respective antigens on a single cell, they align and reconstitute the original CD3-binding site to engage T cells. Employing pr... More

关键词